Nature Communications (Nov 2021)
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
- Dennis Lapuente,
- Jana Fuchs,
- Jonas Willar,
- Ana Vieira Antão,
- Valentina Eberlein,
- Nadja Uhlig,
- Leila Issmail,
- Anna Schmidt,
- Friederike Oltmanns,
- Antonia Sophia Peter,
- Sandra Mueller-Schmucker,
- Pascal Irrgang,
- Kirsten Fraedrich,
- Andrea Cara,
- Markus Hoffmann,
- Stefan Pöhlmann,
- Armin Ensser,
- Cordula Pertl,
- Torsten Willert,
- Christian Thirion,
- Thomas Grunwald,
- Klaus Überla,
- Matthias Tenbusch
Affiliations
- Dennis Lapuente
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Jana Fuchs
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Jonas Willar
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Ana Vieira Antão
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Valentina Eberlein
- Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, IZI
- Nadja Uhlig
- Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, IZI
- Leila Issmail
- Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, IZI
- Anna Schmidt
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Friederike Oltmanns
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Antonia Sophia Peter
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Sandra Mueller-Schmucker
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Pascal Irrgang
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Kirsten Fraedrich
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Andrea Cara
- National Center for Global Health, Istituto Superiore di Sanità
- Markus Hoffmann
- Infection Biology Unit, German Primate Center-Leibniz Institute for Primate Research
- Stefan Pöhlmann
- Infection Biology Unit, German Primate Center-Leibniz Institute for Primate Research
- Armin Ensser
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Cordula Pertl
- Sirion Biotech
- Torsten Willert
- Sirion Biotech
- Christian Thirion
- Sirion Biotech
- Thomas Grunwald
- Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, IZI
- Klaus Überla
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- Matthias Tenbusch
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg
- DOI
- https://doi.org/10.1038/s41467-021-27063-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
While current COVID-19 vaccines provide certain protection, more effective vaccination strategies are still desirable. Here the authors show, using mouse vaccination models, that priming with a systemic mRNA and boosting with an intranasal adenoviral vector vaccine induces comprehensive T cell and mucosal immunity.
